Search

Your search keyword '"Hernandez, Jonathan M."' showing total 739 results

Search Constraints

Start Over You searched for: Author "Hernandez, Jonathan M." Remove constraint Author: "Hernandez, Jonathan M."
739 results on '"Hernandez, Jonathan M."'

Search Results

106. Preclinical Models of Adrenocortical Cancer

108. An RNA Damage Response Network Mediates the Lethality of 5-FU in Clinically Relevant Tumor Types

109. Supplementary Data from Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors

110. Supplementary Figure from Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors

111. Data from Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors

112. Table S3 from Induction of Thioredoxin-Interacting Protein by a Histone Deacetylase Inhibitor, Entinostat, Is Associated with DNA Damage and Apoptosis in Esophageal Adenocarcinoma

113. Tables S1 and S2 from Induction of Thioredoxin-Interacting Protein by a Histone Deacetylase Inhibitor, Entinostat, Is Associated with DNA Damage and Apoptosis in Esophageal Adenocarcinoma

114. Supplemental Figures 1-15 from Induction of Thioredoxin-Interacting Protein by a Histone Deacetylase Inhibitor, Entinostat, Is Associated with DNA Damage and Apoptosis in Esophageal Adenocarcinoma

115. Data from Induction of Thioredoxin-Interacting Protein by a Histone Deacetylase Inhibitor, Entinostat, Is Associated with DNA Damage and Apoptosis in Esophageal Adenocarcinoma

116. Supplementary Figure from Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

117. Anal Carcinoma Surveillance Counterpoint: USA

118. Correction to: Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer

119. sj-pptx-2-gut-10.1177_26345161231188677 – Supplemental material for Survival Trends and Profiling of Gastric Mixed Adenoneuroendocrine Carcinoma (gMANEC) in the Current Era

120. sj-docx-1-gut-10.1177_26345161231188677 – Supplemental material for Survival Trends and Profiling of Gastric Mixed Adenoneuroendocrine Carcinoma (gMANEC) in the Current Era

121. Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer

122. Patient-Derived Organoids and Their Potential for Precision Medicine in Neuroendocrine Tumors

128. ASO Visual Abstract: Cytoreduction and HIPEC for Gastric Carcinomatosis: Multi-institutional Analysis of Two Phase II Clinical Trials

129. A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma

133. Cytoreduction and HIPEC for Gastric Carcinomatosis: Multi-institutional Analysis of Two Phase II Clinical Trials

135. Neutrophil heterogeneity and emergence of a distinct population of CD11b/CD18-activated low-density neutrophils after trauma

146. Author Correction: The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling

149. Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors

Catalog

Books, media, physical & digital resources